BioNTech's Shareholder Mandate and $650M R&D Spend Set the Scene for Pumitamig's ASCO Test

BioNTech secures 92% shareholder approval for costly shift to oncology, with R&D costs soaring to $650M and net loss widening; key ASCO data readouts in May could validate the strategy.

Mainz-based BioNTech secured a decisive shareholder vote on May 15, with 92% of represented capital backing all board proposals — a clear endorsement of the company's costly shift from Covid-19 vaccine maker to oncology powerhouse. The approval lands just as the company’s first-quarter numbers reveal the financial strain of that transition: research and development costs surged past $650 million, while vaccine revenue shrank to a mere $138 million, producing a hefty net loss.

That cash burn is part of a deliberate strategy. BioNTech is sitting on €16.8 billion in cash, equivalents and securities as of March 31, and has authorised a share buyback of up to $1 billion over the next twelve months, aimed primarily at covering equity-based compensation. The company also secured approval for new authorised capital representing up to 50% of current share capital, giving management additional financial flexibility as the pipeline expands.

The stock, however, remains stuck in the doldrums. It closed Friday at €76.95, down 2.22% on the day and 8.01% over the past 30 days. Year to date, the decline stands at nearly 7%, and the shares are trading below their key moving averages. Investors are clearly waiting for proof that the oncology bet will pay off.

Board shake-up signals strategic depth

The AGM also approved an expansion of the supervisory board from six to eight members. Newly elected are Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert, both bringing deep experience in clinical development and commercialisation of cancer drugs. Helmut Jeggle was subsequently named chairman of the board, ensuring continuity in oversight.

The priority areas remain the bispecific immunomodulator Pumitamig and the ADC (antibody-drug conjugate) portfolio, with the next major catalyst just days away. The American Society of Clinical Oncology (ASCO) annual meeting kicks off on May 29 in Chicago, and BioNTech has a packed agenda.

ASCO: The make-or-break moment

The embargo on pre-ASCO abstracts lifts on May 21, giving investors an early glimpse of the data to come. On the conference itself, BioNTech plans to release interim phase 3 data for its CTLA-4 candidate Gotistobart, provide regulatory updates on trastuzumab pamitrecan, and present updates from the ROSETTA lung cancer studies.

The most closely watched presentation will be phase 2 results from the ROSETTA-Lung-02 trial evaluating Pumitamig in combination with chemotherapy against the established standard of care, Merck's Keytruda (pembrolizumab), in first-line non-small cell lung cancer. A positive readout would provide the kind of clinical validation the market has been demanding.

Beyond ASCO, BioNTech has lined up seven late-stage data readouts for 2026 and aims to have 15 phase 3 trials running by year-end. The company also reiterated its non-IFRS revenue guidance of €2.0 billion to €2.3 billion for the full year, and outlined plans to cut €500 million in annual production costs by 2029.

The message from Mainz is clear: the cash is in the bank, the shareholders are on board, and the clinical data is about to speak. For a stock that has shed roughly 95% from its pandemic peak, the next few weeks could determine whether the rebuild has real legs — or whether the selloff has further to run.